Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer withdraws sickle cell drug Oxbryta
Pfizer’s Sickle Cell Drug Candidates Not Hit by Oxbryta Pull
All data considered, the benefit of the therapy, Oxbryta, “no longer outweighs the risk,” Pfizer said in a statement Wednesday. The company, which also announced discontinuing clinical trials as it investigates the findings,
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
Pfizer Takes Sickle Cell Drug Oxbryta Off Global Market, Cites Risk of Death
Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in patients with sickle cell disease. Guggenheim Securities analysts said the setback increases investor frustrations with the company’s business development track record.
14h
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...
GEN
1d
Pfizer Withdraws SCD Drug Oxbryta after EMA Discloses 16 Deaths in Trials
Sixteen patients dosed with
Pfizer
’s sickle cell disease drug
Oxbryta
® (voxelotor) in a pair of clinical trials have died ...
1d
Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Stadiums to serve as shelters
Kotb leaving 'Today'
World's oldest cheese found
Military recruiting rebounds
Chinese submarine sank
Targeted Black residents?
Producing doc on Diddy
Ending password-sharing
Boxes to distribute Narcan
Settles defamation lawsuit
NC board removes 747K
50/50 ball ownership suit
More executives leave
RU hits Ukraine's power grid
Urgent safety alert for 737s
Weekly jobless claims fall
US sanctions crypto network
To withdraw sickle cell drug
Jan. 6 report delayed
US suicides steady, high
ISR rejects ceasefire talks
WI duplicate ballot flap
NIH finds misconduct
On Secret Service failures
Capital goods orders up
Arrives in Luxembourg
Rose announces retirement
US economy grew
Feedback